HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® Plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting

AstraZeneca Reports Improved Overall Survival with Tagrisso and Orpathys in Phase III SAFFRON Lung Cancer Trial

Combination reduced risk of progression or death by 45% and risk of death by 32% against chemotherapy in MET-driven EGFR-mutated NSCLC IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca reported that its Phase III SAFFRON study of Tagrisso plus Orpathys achieved statistically significant progression-free … Read the full press release →

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line ...

— ORPATHYS®plus TAGRISSO®reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine - PressReach

— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® — — ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months — — SAFFRON is the first global Phase III trial to show significant progression-free and … Continue reading "HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simul…

Osimertinib/Savolitinib Improves Survival in MET-Altered EGFR-Mutant NSCLC

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.

Targeted Combination Improves Lung Cancer Survival: ESMO 2026

Osimertinib plus savolitinib cut death risk by 32% versus chemotherapy in selected patients with resistant lung cancer, according to new trial results presented at ESMO 2026.